Dura Pharmaceuticals, Inc. v. Broudo
2005 United States Supreme Court case / From Wikipedia, the free encyclopedia
Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336 (2005), is a securities fraud decision by the Supreme Court of the United States, holding that an inflated purchase price will not by itself constitute or proximately cause the relevant economic loss needed to allege and prove "loss causation."
This article needs additional citations for verification. (February 2010) |
Quick Facts Dura Pharmaceuticals, Inc. v. Broudo, Argued January 12, 2005 Decided April 19, 2005 ...
Dura Pharmaceuticals, Inc. v. Broudo | |
---|---|
Argued January 12, 2005 Decided April 19, 2005 | |
Full case name | Dura Pharmaceuticals, Inc., et al. v. Broudo et al. |
Citations | 544 U.S. 336 (more) 125 S. Ct. 1627; 161 L. Ed. 2d 577; 2005 U.S. LEXIS 3478 |
Case history | |
Prior | 339 F.3d 933 (9th Cir. 2003) |
Holding | |
An inflated purchase price will not by itself constitute or proximately cause the relevant economic loss needed to allege and prove "loss causation." | |
Court membership | |
| |
Case opinion | |
Majority | Breyer, joined by unanimous |
Laws applied | |
109 Stat. 747, 15 U.S.C. §78u-4(b)(4) |
Close